The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Combination of mosunetuzumab with CHOP in DLBCL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses the interim results of a Phase Ib/II study (NCT03677141) investigating the safety and efficacy of a novel combination of mosunetuzumab with CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The addition of mosunetuzumab to the standard CHOP regimen achieved an overall response rate (ORR) of 96%, with a complete response rate of 85% in patients with newly diagnosed DLBCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
